Lanzhou Foci Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of December 2022: 0.08%

Lanzhou Foci Pharmaceutical Co Ltd (002644) has an Asset Resilience Ratio of 0.08% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Lanzhou Foci Pharmaceutical Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥2.00 Million

≈ $292.89K USD Cash + Short-term Investments

Total Assets

CN¥2.61 Billion

≈ $381.40 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2022)

This chart shows how Lanzhou Foci Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Lanzhou Foci Pharmaceutical Co Ltd balance sheet assets.

Liquid Assets Composition Over Time

This chart breaks down Lanzhou Foci Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 002644 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥2.00 Million	0.08%
Total Liquid Assets	CN¥2.00 Million	0.08%

Asset Resilience Insights

Limited Liquidity: Lanzhou Foci Pharmaceutical Co Ltd maintains only 0.08% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Lanzhou Foci Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Lanzhou Foci Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ) ST:SOBI	Drug Manufacturers - Specialty & Generic	1.54%
Yunnan Baiyao Group Co Ltd SHE:000538	Drug Manufacturers - Specialty & Generic	8.38%
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	Drug Manufacturers - Specialty & Generic	6.62%
Takeda Pharmaceutical Co Ltd ADR NYSE:TAK	Drug Manufacturers - Specialty & Generic	4.94%
Harbin Gloria Pharmaceuticals SHE:002437	Drug Manufacturers - Specialty & Generic	9.04%
Jiuzhitang Co Ltd SHE:000989	Drug Manufacturers - Specialty & Generic	7.86%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Jiangsu Kanion Pharmaceutical Co Ltd SHG:600557	Drug Manufacturers - Specialty & Generic	0.29%

Annual Asset Resilience Ratio for Lanzhou Foci Pharmaceutical Co Ltd (2015–2022)

The table below shows the annual Asset Resilience Ratio data for Lanzhou Foci Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	0.08%	CN¥2.00 Million ≈ $292.89K	CN¥2.59 Billion ≈ $378.50 Million	-1.27pp
2020-12-31	1.34%	CN¥32.08 Million ≈ $4.69 Million	CN¥2.39 Billion ≈ $349.32 Million	+1.23pp
2018-12-31	0.11%	CN¥2.90 Million ≈ $424.36K	CN¥2.52 Billion ≈ $369.34 Million	-27.87pp
2017-12-31	27.98%	CN¥657.50 Million ≈ $96.21 Million	CN¥2.35 Billion ≈ $343.85 Million	-6.04pp
2016-12-31	34.03%	CN¥693.00 Million ≈ $101.41 Million	CN¥2.04 Billion ≈ $298.04 Million	+17.73pp
2015-12-31	16.29%	CN¥222.00 Million ≈ $32.49 Million	CN¥1.36 Billion ≈ $199.36 Million	--

pp = percentage points

About Lanzhou Foci Pharmaceutical Co Ltd

SHE:002644 China Drug Manufacturers - Specialty & Generic

Market Cap

$612.00 Million

CN¥4.18 Billion CNY

Market Cap Rank

#11308 Global

#3171 in China

Share Price

CN¥8.19

Change (1 day)

-1.09%

52-Week Range

CN¥6.81 - CN¥10.02

All Time High

CN¥18.02